Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dispenzieri

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Leukemia|March 3, 2006
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocationsW J Chng, R Santana-Dávila, S A Van Wier, et al.
Leukemia|January 25, 2008
Genetic aberrations and survival in plasma cell leukemiaR E Tiedemann, N Gonzalez-Paz, R A Kyle, et al.
Blood Cancer Journal|May 2, 2015
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for deathR Warsame, S K Kumar, M A Gertz, et al.
Bone Marrow Transplantation|April 23, 2013
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral centerA Dispenzieri, K Seenithamby, M Q Lacy, et al.
Blood Cancer Journal|May 30, 2023
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic ExperienceI Vaxman, S K Kumar, F Buadi, et al.
Bone Marrow Transplantation|April 12, 2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapyW I Gonsalves, S V Rajkumar, M A Gertz, et al.
Leukemia|June 17, 2024
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Leukemia|May 22, 2021
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Leukemia|March 3, 2006
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocationsW J Chng, R Santana-Dávila, S A Van Wier, et al.
Leukemia|January 25, 2008
Genetic aberrations and survival in plasma cell leukemiaR E Tiedemann, N Gonzalez-Paz, R A Kyle, et al.
Blood Cancer Journal|May 2, 2015
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for deathR Warsame, S K Kumar, M A Gertz, et al.
Bone Marrow Transplantation|April 23, 2013
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral centerA Dispenzieri, K Seenithamby, M Q Lacy, et al.
Blood Cancer Journal|May 30, 2023
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic ExperienceI Vaxman, S K Kumar, F Buadi, et al.
Bone Marrow Transplantation|April 12, 2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapyW I Gonsalves, S V Rajkumar, M A Gertz, et al.
Leukemia|June 17, 2024
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Leukemia|May 22, 2021
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Pageof 16